-+ 0.00%
-+ 0.00%
-+ 0.00%

NERVGEN PHARMA REPORTS POSITIVE TOPLINE DATA FROM THE CHRONIC COHORT OF ITS PHASE 1B/2A CLINICAL TRIAL EVALUATING NVG-291 IN SPINAL CORD INJURY

Reuters·06/02/2025 11:04:58

Please log in to view news